Genomics research company MedGenome reported ₹98 crore in revenue for Q2 FY26, marking a 19 percent year-on-year increase, while net profit climbed 22 percent to ₹15 crore. Growth was driven by heightened diagnostics adoption in oncology and rare-disease testing across India and Southeast Asia. The firm processed more than 280,000 samples during the quarter and expanded its bioinformatics team by 30 percent. 

Management expects continued double-digit growth as genomic sequencing becomes integral to precision-medicine initiatives and personalized therapy research across hospitals and life-science institutions.